Project Grant R01AR084472
Award Date
8/15/24
Completion Date
7/31/29
Dollars Obligated
$1.7M
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $361,300 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of North Carolina at Chapel Hill. The goal of this 2-year exploratory/developmental project is to use high-throughput small molecule screening and CRISPR screening technologies to identify signaling pathways and therapeutic targets for disease modification in osteoarthritis...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Vanderbilt University a $393,412 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to develop engineered cells as agents for treating osteoarthritis. The project aims to leverage advanced cell design platforms to create synthetic receptor-controlled, joint-resident cells that can detect cartilage degeneration and then upregulate the expression of transgenes to promote...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $618,629 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to The Regents of the University of Colorado to establish a new "microphysiological joint-on-chip" system. The objective is to create a realistic human joint model that can support mechanistic study of arthritic diseases and rapid testing of candidate treatments. The researchers plan to develop...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $123,040 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate the therapeutic role of the NFAT1 transcription factor in osteoarthritis. The 5-year project, which began on August 1, 2024, aims to evaluate the potential of AAV-delivered NFAT1 gene therapy in treating...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1,066,302 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Massachusetts Medical School. The grant, effective April 1, 2025 through March 31, 2029, will fund the creation of a biomedical knowledgebase to promote and facilitate the use of the Osteoarthritis Initiative (OAI), a rich 16-year observational study with comprehensive...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $196,460 to the University of Pittsburgh to test a novel microphysiological system as a tool to study neuroimmune interactions in osteoarthritis pain. The goal is to use this system, which includes cartilage, synovial-like, and innervated tissue, to investigate the influence...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to identify peptides that preferentially localize to osteoarthritic (OA) joints after intravenous injection and leverage these peptides to develop targeted OA drug carriers. The $208,627 award, granted on Jul 11, 2024, will fund research activities at the University of Florida and the...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $220,224 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to The Regents of the University of Colorado, operating as the University of Colorado, with a period of performance from July 4, 2024 to August 31, 2027. The funding will support the development of granular hydrogels for the controlled delivery of immunomodulatory and angiogenic extracellular vesicles to enhance...
This Project Grant award of $413,688 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) aims to identify FDA-approved drugs that can stimulate lubricin production to prevent post-traumatic osteoarthritis. The key products and services to be delivered under this 2-year award include: Developing a phenotypic reporter-based system using genetically engineered human...
The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $410,920 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research (CFDA 93.846) program to The Washington University in St. Louis. The grant will fund a 5-year research project to investigate risk factors for end-stage glenohumeral (shoulder) osteoarthritis, with the objectives of determining associations between occupational exposures and shoulder arthroplasty risk,...